Healthcare Business

Is Tilray’s Growth Enough for Investors?

Tilray Inc. (NASDAQ: TLRY) released third-quarter financial results after the closing bell on Tuesday. The company said that it had a net loss of $0.50 per share and $51.1 million ...
Read Full Story »

Is This DMD Study Sunk After FDA Update?

Solid Biosciences Inc. (NASDAQ: SLDB) shares were absolutely crushed on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has placed its Ignite DMD Phase 1/2 ...
Read Full Story »

Major Biotechs See Rising Tide in Short Interest

The short interest data are out for the most recent settlement date, October 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Why Investors Are Pumping the Brakes on NextCure’s Cancer Treatment

NextCure Inc. (NASDAQ: NXTC) updated clinical results from its early-stage cancer study at the Society for Immunotherapy of Cancer (SITC) annual meeting. As a result, NextCure shares were crushed on ...
Read Full Story »

Is This FDA Update the Death of Lipocine?

Lipocine Inc. (NASDAQ: LPCN) shares absolutely plummeted on Monday after the firm announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding ...
Read Full Story »

Why This Early-Stage Autoimmune and Chronic Inflamatory Trial May Be a Big Hit

Nektar Therapeutics (NASDAQ: NKTR) shares made a handy gain on Monday after the firm announced updated results from its first-in-human Phase 1a study of NKTR-358 for the treatment of autoimmune ...
Read Full Story »

Melanoma Treatment Takes a Big Step Forward

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares jumped on Friday after the firm announced results from its mid-stage metastatic melanoma study at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. ...
Read Full Story »

CVS Is Back: Robust Q3 Earnings, Upbeat Guidance

CVS Health Corp. (NYSE: CVS) released its third-quarter financial results before the markets opened on Wednesday. The firm said that it had $1.84 in earnings per share (EPS) and $64.8 ...
Read Full Story »

Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential

For the first time in years, for 2019 active managers are outperforming index funds, and that should be a loud wake-up call to passive investors. After a more than 10-year ...
Read Full Story »

Many Problems & Caveats Face Any Would-Be Acquirer of Walgreens, Even Warren Buffett

It's one thing to think that there is a value investor's dream awaiting in the shares of Walgreens Boots Alliance Inc. (NASDAQ: WBA). It's another thing to really consider that ...
Read Full Story »

After a 50% Drop, One Analyst Sees Bluebird Bio With Almost 50% Upside

On a day that the Dow Jones industrials and S&P 500 just hit all-time highs, many companies are not exactly feeling the same love as the market darlings that took ...
Read Full Story »

Are Wright Medical Shareholders Getting Enough in the Stryker Acquisition?

Wright Medical Group N.V. (NASDAQ: WMGI) shares exploded on Monday after the announcement that the firm would be acquired by Stryker Corp. (NYSE: SYK). The boards of directors of both ...
Read Full Story »

Meet the Newest FDA Approval in the Fight Against Non-Cardia Gastric Cancer

RedHill Biopharma Ltd. (NASDAQ: RDHL) shares jumped early on Monday after the firm announced that the U.S. Food and Drug Administration (FDA) approved Talicia for the treatment of Helicobacter pylori ...
Read Full Story »

Multiple Sclerosis Treatment Wins Big FDA Approval

Biogen Inc. (NASDAQ: BIIB) and Alkermes PLC (NASDAQ: ALKS) announced an update from the U.S. Food and Drug Administration on Wednesday morning. The FDA approved Vumerity for the treatment of ...
Read Full Story »